WVE on Nasdaq

Wave Life Sciences

Biotechnology company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PALVELLA THERAPEUTICS, INC., Verona Pharma or Xilio Therapeutics, Inc., or pick any stock.

  • TickerWVE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston1
  • Websitewavelifesciences.com
  • Incorporated inDE4
  • Business address733 Concord Avenue, Cambridge, Ma 021384
  • Filer categoryLarge accelerated filer4
  • Legal formPrivate Company Limited by Shares3
  • LEI54930070006GPKFYZ8133
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered address7 STRAITS VIEW, #12-00, MARINA ONE EAST TOWER, 018936 Singapore, Singapore3
  • Registered withAccounting and Corporate Regulatory Authority (ACRA), 201218209G3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our pipeline is focused on our obesity (WVE-007), alpha-1 antitrypsin deficiency (“AATD”) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs for Duchenne muscular dystrophy (“DMD”) and Huntington’s disease (“HD”), as…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-504.1%Operating margin6
-478.3%Net margin6
-60.5%Revenue growth, 20256
-39.4%Return on equity6
-$188.2MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$182.8M

Out of $42.7M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$42.7M in 2025+167% since 2019
0$50.0M$100.0M$150.0M2019: $16.0M$16.0M20192020: $20.1M$20.1M2020+26%2021: $41.0M$41.0M2021+104%2022: $3.6M$3.6M2022−91%2023: $113.3M$113.3M2023+3005%2024: $108.3M$108.3M2024−4%2025: $42.7M$42.7M2025−61%
Operating income789106-$215.4M in 2025+3% since 2019
-$300.0M-$200.0M-$100.0M02019: -$208.3M-$208.3M20192020: -$153.4M-$153.4M2020−26%2021: -$127.0M-$127.0M2021−17%2022: -$162.7M-$162.7M2022+28%2023: -$68.0M-$68.0M2023−58%2024: -$110.4M-$110.4M2024+62%2025: -$215.4M-$215.4M2025+95%
Net income789106-$204.4M in 2025+6% since 2019
-$300.0M-$200.0M-$100.0M02019: -$193.6M-$193.6M20192020: -$149.9M-$149.9M2020−23%2021: -$122.2M-$122.2M2021−18%2022: -$161.8M-$161.8M2022+32%2023: -$57.5M-$57.5M2023−64%2024: -$97.0M-$97.0M2024+69%2025: -$204.4M-$204.4M2025+111%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenue$42.7M$108.3M$113.3M
Research and development$182.8M$159.7M$130.0M
General and administrative$75.3M$59.0M$51.3M
Total operating expenses$258.1M$218.7M$181.3M
Loss from operations-$215.4M-$110.4M-$68.0M
Dividend income and interest income, net$10.5M$10.2M$7.9M
Other income, net$527.0K$3.2M$1.9M
Total other income, net$11.0M$13.4M$9.8M
Loss before income taxes-$204.4M-$97.0M-$58.2M
Income tax benefit$0$0$677.0K
Net loss-$204.4M-$97.0M-$57.5M
Net loss per share attributable to ordinary shareholders - basic-$1.21-$0.70-$0.54
Net loss per share attributable to ordinary shareholders - diluted-$1.21-$0.70-$0.54
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - basic168.6M shares138.3M shares106.1M shares
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - diluted168.6M shares138.3M shares106.1M shares
Foreign currency translation gain (loss)$12.0K-$138.0K-$95.0K
Comprehensive loss-$204.4M-$97.1M-$57.6M

Compare Wave Life Sciences with another company

Leadership

Who has led Wave Life Sciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Paul Bolno2018–now

President

  1. Paul Bolno2018–now

Chief financial officer

  1. Keith Regnante2016–2019
  2. David G. Gaiero2020
  3. Kyle Moran2020–now
20202025
Board members and other officers (21)

Former names

  • Wave Life Sciences Ltd.Jul 6, 2017 to Jul 30, 20264
  • Wave Life Sciences Pte LtdFeb 2, 2015 to Nov 2, 20154

Timeline

  1. Feb 21, 2018New chief executive Paul Bolno becomes CEO14
  2. Nov 11, 2015Went public Listed on NASDAQ1

Filings

360 filings to the SEC since October 2021: 11 annual reports, 15 quarterly reports, 76 major events, 126 insider forms, 44 large holders, 88 other. The latest 20:

  1. Oct 14, 2026ARS EDGAR
  2. Oct 14, 2026DEF 14A EDGAR
  3. Oct 7, 20264 EDGAR
  4. Oct 7, 20264 EDGAR
  5. Oct 7, 20264 EDGAR
  6. Oct 7, 20264 EDGAR
  7. Oct 7, 20264 EDGAR
  8. Oct 7, 20264 EDGAR
  9. Oct 7, 20264 EDGAR
  10. Oct 7, 20264 EDGAR
  11. Aug 14, 2026EFFECT EDGAR
  12. Aug 13, 20264 EDGAR
  13. Aug 13, 20264 EDGAR
  14. Aug 13, 20264 EDGAR
  15. Aug 13, 20264 EDGAR
  16. Aug 12, 2026144 EDGAR
  17. Aug 11, 2026144 EDGAR
  18. Aug 11, 2026SCHEDULE 13D/A EDGAR
  19. Aug 10, 202615-12G EDGAR
  20. Aug 10, 2026POS AM EDGAR

The 360 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

62 open-market trades by officers, directors and large owners since October 2021: 10 buys and 52 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 12, 2026Rawcliffe AdrianDirectorSale12,700$5.29$67.2KForm 4
Aug 11, 2026Wagner Heidi LDirectorSale7,000$6.01$42.1KForm 4
Aug 11, 2026TAKANASHI KENDirectorSale3,864$6.01$23.2KForm 4
Aug 11, 2026Tan Aik NaDirectorSale432$6.01$2.6KForm 4
Mar 30, 2026RA CAPITAL MANAGEMENT, L.P.DirectorBuy971,091$6.50$6.3MForm 4
Mar 27, 2026RA CAPITAL MANAGEMENT, L.P.DirectorBuy2,495,623$6.43$16.0MForm 4
Mar 26, 2026RA CAPITAL MANAGEMENT, L.P.DirectorBuy5,305,782$6.08$32.3MForm 4
Feb 26, 2026Francis ChrisSee RemarksSale33,194$15.05$499.5KForm 4
Feb 9, 2026Moran KyleChief Financial OfficerSale3,588$13.45$48.3KForm 4
Feb 9, 2026BOLNO PAULPresident and CEOSale10,480$13.45$141.0KForm 4
Feb 9, 2026Francis ChrisSee RemarksSale1,883$13.45$25.3KForm 4
Feb 9, 2026Vargeese ChandraSee RemarksSale3,228$13.45$43.4KForm 4
Jan 2, 2026Francis ChrisSee RemarksSale9,375$16.03$150.3KForm 4
Dec 11, 2025GSK plc10% ownerBuy1,470,000$19.00$27.9MForm 4
Dec 9, 2025Moran KyleChief Financial OfficerSale50,036$20.03$1.0MForm 4
Dec 8, 2025Rawcliffe AdrianDirectorSale42,000$15.00$630.0KForm 4
Dec 8, 2025Wagner Heidi LDirectorSale14,000$13.50$189.0KForm 4
Dec 8, 2025HENRY CHRISTIAN ODirectorSale93,445$14.65$1.4MForm 4
Dec 8, 2025Tan Aik NaDirectorSale134,218$13.58$1.8MForm 4
Dec 8, 2025Verdine Gregory L.DirectorSale20,000$13.47$269.5KForm 4

All 62 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kennedy Capital Management LLC429,121$2.5M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52